A carregar...

Ambrisentan for the treatment of pulmonary arterial hypertension

Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasoconstrictor with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Casserly, Brian, Klinger, James R
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761178/
https://ncbi.nlm.nih.gov/pubmed/19920913
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!